# The BENeFiTS Trial in Beta Thalassemia Intermedia

> **NCT04432623** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Phoenicia BioScience** · enrollment: 36 (estimated)

## Conditions studied

- Beta Thalassemia Intermedia
- Sickle Cell Disease

## Interventions

- **DRUG:** Benserazide Only Product

## Key facts

- **NCT ID:** NCT04432623
- **Lead sponsor:** Phoenicia BioScience
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-10-05
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04432623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04432623, "The BENeFiTS Trial in Beta Thalassemia Intermedia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04432623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*